Acquisitions24 Sept 2026, 10:05 pm
Dr. Lal PathLabs Acquires 70% Stake in SN Genelab for up to ₹168 Cr
AI Summary
Dr. Lal PathLabs Ltd announced today that its Board of Directors has approved the acquisition of a 70% stake in SN Genelab Private Limited, a diagnostics genomics company. The deal, valued at up to INR 168 Crores plus performance-linked earn-out, is expected to close by November 30, 2026. This strategic acquisition aims to enhance Dr. Lal PathLabs' expertise in genomics and expand its advanced diagnostic service offerings. SN Genelab reported a turnover of INR 57.96 Crores in FY26. Post-acquisition, SN Genelab will become a subsidiary of Dr. Lal PathLabs.
Key Highlights
- Dr. Lal PathLabs to acquire 70% stake in SN Genelab.
- Acquisition cost up to ₹168 Cr plus earn-out.
- Deal aims to strengthen genomics expertise and service portfolio.
- SN Genelab's FY26 turnover was ₹57.96 Crores.
- Transaction expected to complete by November 30, 2026.
Price Impact
More from LALPATHLAB